Should you buy Neurocrine Biosciences (NBIX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Revenue Growth At Value Peg→Stable
- Wide Moat High Quality Compounder→Stable
- Earnings Beat Track Record↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat High Quality Compounder
Trip ifPiotroski F-Score falls below 7 or quality score drops below 7.0.
- P2Revenue Growth At Value Peg
Trip ifRevenue growth falls below 15% year-over-year for 2 consecutive quarters.
- P3Earnings Beat Track Record
Trip ifThe company misses consensus EPS estimates by more than 15% in 2 of the next 4 quarters.
- P4Single Product Concentration Risk
Trip ifAny single product accounts for more than 90% of total revenue for 2 consecutive quarters without pipeline progress reducing the dependency.
How the engine reached this verdict
TrendMatrix's engine output for Neurocrine Biosciences, Inc. (NBIX) is STRONG_BUY_WAIT with high conviction, score 7.1/10 at $156.72. The C-path quality+growth combination cleared its gates — quality 8.3 and growth 9.1 — with 4.03 asymmetric R:R supporting the read.
The engine's suggested entry zone is $152.16, currently 3.0% above entry. Target $190.55, stop $143.76, asymmetric R:R 4.03. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 1.3% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF); Sector modifier (Healthcare): +0.5; Strong earnings beat streak (3/4). On the bear side: Concentration risk — Product: INGREZZA. Active engine warnings: News modifier capped: WAIT cannot upgrade to NOW via sentiment alone.
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 4.03); the verdict flips to HOLD if overall score deteriorates by ~0.7.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates NBIX — 10-dimension breakdown →
Bull case
- ▸V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (3/4)
Bear case
- ▸Concentration risk — Product: INGREZZA